Share Price and Basic Stock Data
Last Updated: January 6, 2026, 9:12 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Decipher Labs Ltd, operating in the pharmaceuticals sector, reported a current share price of ₹9.34 and a market capitalization of ₹9.44 Cr. The company’s revenue trends reflect significant fluctuations over recent years. Sales peaked at ₹65.32 Cr in March 2022, but subsequently declined to ₹45.57 Cr in March 2023 and are projected to further decrease to ₹35.88 Cr in March 2024. The trailing twelve months (TTM) revenue stood at ₹16.53 Cr, indicating a stark contrast to previous peaks, highlighting potential challenges in maintaining market demand. Quarterly sales have also exhibited volatility, with the most recent quarter ending September 2023 reporting ₹7.49 Cr, a drop from ₹11.06 Cr in December 2022. This trend underscores the necessity for Decipher Labs to reevaluate its market strategies and operational efficiencies to stabilize revenue streams.
Profitability and Efficiency Metrics
The profitability metrics for Decipher Labs reveal a concerning trend, with a net profit of ₹-8.11 Cr as of the latest reporting period. The operating profit margin (OPM) was reported at a mere 2.78%, which is significantly below industry averages, suggesting inefficiencies in cost management. The company has experienced a negative operating profit in multiple quarters, with the worst recorded at ₹-6.58 Cr for March 2025. Furthermore, the return on equity (ROE) stood at 1.16%, while return on capital employed (ROCE) was at 4.67%, both indicating suboptimal returns relative to equity and capital invested. The cash conversion cycle (CCC) of 68.12 days further complicates the efficiency narrative, as it suggests potential delays in converting inventory into cash, which can strain liquidity.
Balance Sheet Strength and Financial Ratios
Decipher Labs’ balance sheet reflects a precarious financial position, characterized by total borrowings of ₹0.43 Cr and reserves of ₹9.04 Cr. The current ratio, reported at 7.24, indicates a strong liquidity position, suggesting that the company can cover its short-term liabilities comfortably. However, the interest coverage ratio (ICR) stands at 0.00x, implying that the company is not generating sufficient earnings to cover interest obligations. The price-to-book value (P/BV) ratio of 0.46x suggests that the market undervalues the company’s equity relative to its book value, which could signal potential investment opportunities if the company can improve its operational performance. The total debt to equity ratio is notably low at 0.01, indicating minimal leverage, a potential strength in capital structure management.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Decipher Labs indicates a significant public ownership of 83.57%, while promoter holdings stand at 16.43%. This distribution suggests a lack of institutional investor confidence, as foreign institutional investors (FIIs) and domestic institutional investors (DIIs) are not represented in the shareholding structure. Over the reporting periods, the number of shareholders has declined from 40,027 in December 2022 to 30,174 as of September 2025, reflecting a possible erosion of investor confidence. The stability of promoter shareholding at 16.43% across multiple quarters may reassure some investors, but the high public ownership coupled with declining shareholder numbers raises concerns about the company’s attractiveness in the market. This trend could hinder future capital-raising efforts and affect strategic decisions.
Outlook, Risks, and Final Insight
Looking ahead, Decipher Labs faces both opportunities and risks that will shape its future. The company’s ability to enhance operational efficiencies and stabilize revenue streams is critical for recovery. However, risks include persistent negative profitability, low investor confidence, and increasing competition in the pharmaceuticals sector. The company must also navigate the challenges of managing its cash conversion cycle effectively. If Decipher Labs can successfully implement strategic initiatives to improve sales and profitability, it may attract renewed investor interest and potentially reverse the declining trend in shareholder numbers. Conversely, failure to address these operational and financial challenges could lead to further deterioration of its market position and financial health.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 131 Cr. | 104 | 214/84.3 | 29.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,602 Cr. | 420 | 479/192 | 95.3 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 56.0 Cr. | 38.2 | 38.8/17.0 | 133 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,486.28 Cr | 1,152.73 | 54.41 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.12 | 11.06 | 9.78 | 9.51 | 7.49 | 8.29 | 10.59 | 7.44 | 5.87 | 5.80 | 3.50 | 2.92 | 4.31 |
| Expenses | 12.98 | 14.02 | 13.63 | 9.65 | 9.66 | 8.16 | 9.38 | 6.13 | 7.20 | 6.43 | 10.08 | 6.24 | 4.19 |
| Operating Profit | -0.86 | -2.96 | -3.85 | -0.14 | -2.17 | 0.13 | 1.21 | 1.31 | -1.33 | -0.63 | -6.58 | -3.32 | 0.12 |
| OPM % | -7.10% | -26.76% | -39.37% | -1.47% | -28.97% | 1.57% | 11.43% | 17.61% | -22.66% | -10.86% | -188.00% | -113.70% | 2.78% |
| Other Income | 2.66 | -4.55 | 0.15 | 0.01 | 0.14 | 0.00 | 0.27 | 0.16 | 0.12 | 0.17 | 0.87 | 0.01 | 0.02 |
| Interest | 0.12 | 0.13 | 0.07 | 0.01 | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.10 | 0.11 | 0.12 | 0.11 | 0.11 | 0.12 | 0.11 | 0.11 | 0.12 | 0.12 | 0.13 | 0.12 | 0.13 |
| Profit before tax | 1.58 | -7.75 | -3.89 | -0.25 | -2.14 | 0.01 | 1.16 | 1.36 | -1.33 | -0.58 | -5.84 | -3.43 | 0.01 |
| Tax % | 24.05% | 0.13% | 9.77% | 280.00% | -9.35% | 0.00% | -3.45% | 30.15% | 0.00% | 1.72% | -29.62% | 0.00% | 0.00% |
| Net Profit | 1.19 | -7.75 | -4.27 | -0.95 | -1.94 | 0.01 | 1.20 | 0.95 | -1.33 | -0.59 | -4.11 | -3.43 | 0.02 |
| EPS in Rs | 1.18 | -7.67 | -4.23 | -0.94 | -1.92 | 0.01 | 1.19 | 0.94 | -1.32 | -0.58 | -4.07 | -3.40 | 0.02 |
Last Updated: December 27, 2025, 8:32 am
Below is a detailed analysis of the quarterly data for Decipher Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 4.31 Cr.. The value appears strong and on an upward trend. It has increased from 2.92 Cr. (Jun 2025) to 4.31 Cr., marking an increase of 1.39 Cr..
- For Expenses, as of Sep 2025, the value is 4.19 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.24 Cr. (Jun 2025) to 4.19 Cr., marking a decrease of 2.05 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.12 Cr.. The value appears strong and on an upward trend. It has increased from -3.32 Cr. (Jun 2025) to 0.12 Cr., marking an increase of 3.44 Cr..
- For OPM %, as of Sep 2025, the value is 2.78%. The value appears strong and on an upward trend. It has increased from -113.70% (Jun 2025) to 2.78%, marking an increase of 116.48%.
- For Other Income, as of Sep 2025, the value is 0.02 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Jun 2025) to 0.02 Cr., marking an increase of 0.01 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.13 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.12 Cr. (Jun 2025) to 0.13 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from -3.43 Cr. (Jun 2025) to 0.01 Cr., marking an increase of 3.44 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 0.02 Cr.. The value appears strong and on an upward trend. It has increased from -3.43 Cr. (Jun 2025) to 0.02 Cr., marking an increase of 3.45 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.02. The value appears strong and on an upward trend. It has increased from -3.40 (Jun 2025) to 0.02, marking an increase of 3.42.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:52 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.02 | 8.06 | 23.99 | 55.56 | 65.32 | 45.57 | 35.88 | 22.61 | 16.53 |
| Expenses | 0.95 | 7.61 | 21.47 | 52.08 | 59.29 | 49.74 | 36.56 | 24.50 | 26.94 |
| Operating Profit | 0.07 | 0.45 | 2.52 | 3.48 | 6.03 | -4.17 | -0.68 | -1.89 | -10.41 |
| OPM % | 6.86% | 5.58% | 10.50% | 6.26% | 9.23% | -9.15% | -1.90% | -8.36% | -62.98% |
| Other Income | 0.11 | 0.00 | 0.27 | 0.65 | 7.67 | 0.92 | 0.16 | -4.02 | 1.07 |
| Interest | 0.00 | 0.01 | 0.77 | 1.17 | 0.48 | 0.48 | 0.24 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.56 | 0.82 | 0.87 | 0.43 | 0.45 | 0.48 | 0.50 |
| Profit before tax | 0.18 | 0.44 | 1.46 | 2.14 | 12.35 | -4.16 | -1.21 | -6.39 | -9.84 |
| Tax % | 0.00% | 9.09% | 25.34% | 34.58% | 7.85% | -35.58% | 38.02% | -20.50% | |
| Net Profit | 0.18 | 0.41 | 1.10 | 1.40 | 11.38 | -2.68 | -1.68 | -5.08 | -8.11 |
| EPS in Rs | 0.22 | 0.51 | 1.09 | 1.39 | 11.27 | -2.65 | -1.66 | -5.03 | -8.03 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 127.78% | 168.29% | 27.27% | 712.86% | -123.55% | 37.31% | -202.38% |
| Change in YoY Net Profit Growth (%) | 0.00% | 40.51% | -141.02% | 685.58% | -836.41% | 160.86% | -239.69% |
Decipher Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -30% |
| TTM: | -47% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -4400% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -15% |
| 3 Years: | -39% |
| 1 Year: | -41% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | -4% |
| Last Year: | -23% |
Last Updated: September 5, 2025, 3:11 pm
Balance Sheet
Last Updated: December 4, 2025, 2:43 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.00 | 8.00 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves | -5.88 | -5.47 | 2.46 | 3.59 | 14.07 | 13.11 | 11.76 | 12.76 | 9.04 |
| Borrowings | 0.13 | 0.20 | 11.28 | 16.39 | 10.32 | 0.95 | 0.00 | 0.24 | 0.43 |
| Other Liabilities | 0.71 | 3.61 | 11.55 | 8.64 | 7.46 | 4.01 | 11.77 | 2.66 | 4.19 |
| Total Liabilities | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 | 23.76 |
| Fixed Assets | 0.00 | 0.01 | 4.98 | 4.43 | 2.83 | 3.31 | 2.91 | 2.54 | 2.67 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 3.76 | 3.39 | 0.26 | 0.00 |
| Other Assets | 2.96 | 6.33 | 30.41 | 34.29 | 38.86 | 21.10 | 27.33 | 22.96 | 21.09 |
| Total Assets | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 | 23.76 |
Below is a detailed analysis of the balance sheet data for Decipher Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.10 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.10 Cr..
- For Reserves, as of Sep 2025, the value is 9.04 Cr.. The value appears to be declining and may need further review. It has decreased from 12.76 Cr. (Mar 2025) to 9.04 Cr., marking a decrease of 3.72 Cr..
- For Borrowings, as of Sep 2025, the value is 0.43 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.24 Cr. (Mar 2025) to 0.43 Cr., marking an increase of 0.19 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.66 Cr. (Mar 2025) to 4.19 Cr., marking an increase of 1.53 Cr..
- For Total Liabilities, as of Sep 2025, the value is 23.76 Cr.. The value appears to be improving (decreasing). It has decreased from 25.76 Cr. (Mar 2025) to 23.76 Cr., marking a decrease of 2.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2.67 Cr.. The value appears strong and on an upward trend. It has increased from 2.54 Cr. (Mar 2025) to 2.67 Cr., marking an increase of 0.13 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.26 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.26 Cr..
- For Other Assets, as of Sep 2025, the value is 21.09 Cr.. The value appears to be declining and may need further review. It has decreased from 22.96 Cr. (Mar 2025) to 21.09 Cr., marking a decrease of 1.87 Cr..
- For Total Assets, as of Sep 2025, the value is 23.76 Cr.. The value appears to be declining and may need further review. It has decreased from 25.76 Cr. (Mar 2025) to 23.76 Cr., marking a decrease of 2.00 Cr..
Notably, the Reserves (9.04 Cr.) exceed the Borrowings (0.43 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.06 | 0.25 | -8.76 | -12.91 | -4.29 | -5.12 | -0.68 | -2.13 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 211.13 | 156.69 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Inventory Days | 91.25 | 19.70 | 0.00 | |||||
| Days Payable | 511.00 | 192.66 | ||||||
| Cash Conversion Cycle | -208.62 | -16.27 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Working Capital Days | 751.47 | 99.63 | -2.13 | -11.50 | 65.43 | 61.67 | 36.52 | 247.48 |
| ROCE % | 18.07% | 16.79% | 12.28% | 39.74% | 9.45% | -3.09% | -4.67% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -5.03 | -1.66 | -2.66 | 11.27 | 1.39 |
| Diluted EPS (Rs.) | -5.03 | -1.66 | -2.66 | 11.27 | 1.39 |
| Cash EPS (Rs.) | -4.56 | -1.21 | -2.23 | 12.13 | 2.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 22.63 | 21.64 | 22.98 | 23.93 | 13.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 22.63 | 21.64 | 22.98 | 23.93 | 13.55 |
| Revenue From Operations / Share (Rs.) | 22.39 | 35.52 | 45.12 | 64.67 | 55.01 |
| PBDIT / Share (Rs.) | -5.85 | -0.53 | -1.05 | 13.56 | 4.05 |
| PBIT / Share (Rs.) | -6.32 | -0.98 | -1.48 | 12.71 | 3.24 |
| PBT / Share (Rs.) | -6.32 | -1.20 | -4.12 | 12.23 | 2.12 |
| Net Profit / Share (Rs.) | -5.03 | -1.66 | -2.65 | 11.27 | 1.39 |
| NP After MI And SOA / Share (Rs.) | -5.03 | -1.66 | -2.65 | 11.27 | 1.39 |
| PBDIT Margin (%) | -26.13 | -1.50 | -2.33 | 20.97 | 7.37 |
| PBIT Margin (%) | -28.24 | -2.76 | -3.27 | 19.64 | 5.89 |
| PBT Margin (%) | -28.24 | -3.37 | -9.12 | 18.91 | 3.85 |
| Net Profit Margin (%) | -22.46 | -4.67 | -5.88 | 17.42 | 2.52 |
| NP After MI And SOA Margin (%) | -22.46 | -4.67 | -5.88 | 17.42 | 2.52 |
| Return on Networth / Equity (%) | -22.22 | -7.66 | -11.55 | 47.10 | 10.24 |
| Return on Capital Employeed (%) | -27.94 | -4.54 | -6.17 | 41.60 | 15.30 |
| Return On Assets (%) | -19.71 | -4.98 | -9.52 | 27.13 | 3.62 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.04 | 0.27 | 0.49 |
| Total Debt / Equity (X) | 0.01 | 0.00 | 0.04 | 0.42 | 0.63 |
| Asset Turnover Ratio (%) | 0.76 | 1.16 | 1.30 | 0.03 | 0.04 |
| Current Ratio (X) | 7.24 | 2.10 | 5.01 | 3.44 | 1.30 |
| Quick Ratio (X) | 7.24 | 2.10 | 5.01 | 3.44 | 1.30 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.82 |
| Interest Coverage Ratio (X) | 0.00 | -2.49 | -2.49 | 28.74 | 3.61 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | -6.70 | -0.03 | 24.89 | 2.24 |
| Enterprise Value (Cr.) | 8.05 | 5.60 | 7.86 | 48.39 | 35.56 |
| EV / Net Operating Revenue (X) | 0.35 | 0.15 | 0.17 | 0.74 | 0.64 |
| EV / EBITDA (X) | -1.36 | -10.36 | -7.39 | 3.53 | 8.68 |
| MarketCap / Net Operating Revenue (X) | 0.46 | 0.41 | 0.31 | 0.81 | 0.60 |
| Price / BV (X) | 0.46 | 0.68 | 0.61 | 2.21 | 2.47 |
| Price / Net Operating Revenue (X) | 0.46 | 0.41 | 0.31 | 0.81 | 0.60 |
| EarningsYield | -0.47 | -0.11 | -0.18 | 0.21 | 0.04 |
After reviewing the key financial ratios for Decipher Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 5. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For Diluted EPS (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 5. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For Cash EPS (Rs.), as of Mar 25, the value is -4.56. This value is below the healthy minimum of 3. It has decreased from -1.21 (Mar 24) to -4.56, marking a decrease of 3.35.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.63. It has increased from 21.64 (Mar 24) to 22.63, marking an increase of 0.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.63. It has increased from 21.64 (Mar 24) to 22.63, marking an increase of 0.99.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 22.39. It has decreased from 35.52 (Mar 24) to 22.39, marking a decrease of 13.13.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -5.85. This value is below the healthy minimum of 2. It has decreased from -0.53 (Mar 24) to -5.85, marking a decrease of 5.32.
- For PBIT / Share (Rs.), as of Mar 25, the value is -6.32. This value is below the healthy minimum of 0. It has decreased from -0.98 (Mar 24) to -6.32, marking a decrease of 5.34.
- For PBT / Share (Rs.), as of Mar 25, the value is -6.32. This value is below the healthy minimum of 0. It has decreased from -1.20 (Mar 24) to -6.32, marking a decrease of 5.12.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 2. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 2. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For PBDIT Margin (%), as of Mar 25, the value is -26.13. This value is below the healthy minimum of 10. It has decreased from -1.50 (Mar 24) to -26.13, marking a decrease of 24.63.
- For PBIT Margin (%), as of Mar 25, the value is -28.24. This value is below the healthy minimum of 10. It has decreased from -2.76 (Mar 24) to -28.24, marking a decrease of 25.48.
- For PBT Margin (%), as of Mar 25, the value is -28.24. This value is below the healthy minimum of 10. It has decreased from -3.37 (Mar 24) to -28.24, marking a decrease of 24.87.
- For Net Profit Margin (%), as of Mar 25, the value is -22.46. This value is below the healthy minimum of 5. It has decreased from -4.67 (Mar 24) to -22.46, marking a decrease of 17.79.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -22.46. This value is below the healthy minimum of 8. It has decreased from -4.67 (Mar 24) to -22.46, marking a decrease of 17.79.
- For Return on Networth / Equity (%), as of Mar 25, the value is -22.22. This value is below the healthy minimum of 15. It has decreased from -7.66 (Mar 24) to -22.22, marking a decrease of 14.56.
- For Return on Capital Employeed (%), as of Mar 25, the value is -27.94. This value is below the healthy minimum of 10. It has decreased from -4.54 (Mar 24) to -27.94, marking a decrease of 23.40.
- For Return On Assets (%), as of Mar 25, the value is -19.71. This value is below the healthy minimum of 5. It has decreased from -4.98 (Mar 24) to -19.71, marking a decrease of 14.73.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has decreased from 1.16 (Mar 24) to 0.76, marking a decrease of 0.40.
- For Current Ratio (X), as of Mar 25, the value is 7.24. This value exceeds the healthy maximum of 3. It has increased from 2.10 (Mar 24) to 7.24, marking an increase of 5.14.
- For Quick Ratio (X), as of Mar 25, the value is 7.24. This value exceeds the healthy maximum of 2. It has increased from 2.10 (Mar 24) to 7.24, marking an increase of 5.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has increased from -2.49 (Mar 24) to 0.00, marking an increase of 2.49.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has increased from -6.70 (Mar 24) to 0.00, marking an increase of 6.70.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8.05. It has increased from 5.60 (Mar 24) to 8.05, marking an increase of 2.45.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 1. It has increased from 0.15 (Mar 24) to 0.35, marking an increase of 0.20.
- For EV / EBITDA (X), as of Mar 25, the value is -1.36. This value is below the healthy minimum of 5. It has increased from -10.36 (Mar 24) to -1.36, marking an increase of 9.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.41 (Mar 24) to 0.46, marking an increase of 0.05.
- For Price / BV (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has decreased from 0.68 (Mar 24) to 0.46, marking a decrease of 0.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.41 (Mar 24) to 0.46, marking an increase of 0.05.
- For EarningsYield, as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.11 (Mar 24) to -0.47, marking a decrease of 0.36.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Decipher Labs Ltd:
- Net Profit Margin: -22.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -27.94% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -22.22% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 7.24
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 54.41)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -22.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-2, Q2, 5th Floor, Cyber Towers, Hyderabad Telangana 500081 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sushant Mohan Lal | Non Executive Director |
| Mr. G Venkateswara Rao | Independent Director |
| Mrs. Lakshmi Vijaya Nimmala | Independent Director |
| Mrs. Gayathri Raghuram | Independent Director |
| Mr. Janaki Ram Ajjarapu | Non Executive Director |
FAQ
What is the intrinsic value of Decipher Labs Ltd?
Decipher Labs Ltd's intrinsic value (as of 06 January 2026) is ₹2.70 which is 71.09% lower the current market price of ₹9.34, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹9.44 Cr. market cap, FY2025-2026 high/low of ₹15.9/9.00, reserves of ₹9.04 Cr, and liabilities of ₹23.76 Cr.
What is the Market Cap of Decipher Labs Ltd?
The Market Cap of Decipher Labs Ltd is 9.44 Cr..
What is the current Stock Price of Decipher Labs Ltd as on 06 January 2026?
The current stock price of Decipher Labs Ltd as on 06 January 2026 is ₹9.34.
What is the High / Low of Decipher Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Decipher Labs Ltd stocks is ₹15.9/9.00.
What is the Stock P/E of Decipher Labs Ltd?
The Stock P/E of Decipher Labs Ltd is .
What is the Book Value of Decipher Labs Ltd?
The Book Value of Decipher Labs Ltd is 19.0.
What is the Dividend Yield of Decipher Labs Ltd?
The Dividend Yield of Decipher Labs Ltd is 0.00 %.
What is the ROCE of Decipher Labs Ltd?
The ROCE of Decipher Labs Ltd is 4.67 %.
What is the ROE of Decipher Labs Ltd?
The ROE of Decipher Labs Ltd is 1.16 %.
What is the Face Value of Decipher Labs Ltd?
The Face Value of Decipher Labs Ltd is 10.0.